Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Transmedics Group Inc (NASDAQ: TMDX) closed at $112.46 down -9.87% from its previous closing price of $124.78. In other words, the price has decreased by -$9.87 from its previous closing price. On the day, 2.55 million shares were traded. TMDX stock price reached its highest trading level at $123.4999 during the session, while it also had its lowest trading level at $109.59.
Ratios:
For a deeper understanding of Transmedics Group Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.32 and its Current Ratio is at 9.10. In the meantime, Its Debt-to-Equity ratio is 1.95 whereas as Long-Term Debt/Eq ratio is at 1.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 09 ’25 when Ranganath Anil P. sold 686 shares for $139.80 per share. The transaction valued at 95,903 led to the insider holds 13,955 shares of the business.
Basile Edward M sold 5,000 shares of TMDX for $632,250 on May 27 ’25. The Director now owns 2,866 shares after completing the transaction at $126.45 per share. On May 27 ’25, another insider, EDWARD BASILE, who serves as the Director of the company, bought 5,000 shares for $126.45 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 3804948992 and an Enterprise Value of 4742332928. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 82.65, and their Forward P/E ratio for the next fiscal year is 44.33. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.74. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.79 while its Price-to-Book (P/B) ratio in mrq is 14.29. Its current Enterprise Value per Revenue stands at 9.713 whereas that against EBITDA is 63.99.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.10, which has changed by -0.2209214 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is -8.86%, while the 200-Day Moving Average is calculated to be 19.53%.
Shares Statistics:
For the past three months, TMDX has traded an average of 983.92K shares per day and 831890 over the past ten days. A total of 33.83M shares are outstanding, with a floating share count of 32.58M. Insiders hold about 3.71% of the company’s shares, while institutions hold 117.91% stake in the company. Shares short for TMDX as of 1749772800 were 7860937 with a Short Ratio of 8.18, compared to 1747267200 on 8104743. Therefore, it implies a Short% of Shares Outstanding of 7860937 and a Short% of Float of 40.14.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
